Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.

Pfizer

Status: Completed

Conditions: Renal Cell Carcinoma

Treatments: Other: Non-interventional

Study type: Observational

Funder types: Other; NETWORK; Industry

Identifiers

NCT01339962

A6181203

DARENCA STUDY 2

Details and patient eligibility

About

Non-interventional study. Data obtained by patient chart reviews.

Retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell carcinoma treated in Denmark from 2006-2010 Safety, prognostic factors, predictive factors and co-morbidity assessed by Charlson Comorbidity Index.

The following drugs will be evaluated: Sunitinib, Sorafenib, Temsirolimus, Everolimus, Aldesleukin, Interferon-alfa-2b.

Full description

No sampling. All eligible patients will be included.

Enrollment: 1,073 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Metastatic renal cell carcinoma

Exclusion criteria

None

Trial design

1,073 participants in 1 patient group

Non-Interventional Study

Description:

Outcomes Research Study

Treatment:

Other: Non-interventional